The FDA’s approval of the first point-of-care total PSA test for prostate cancer has the potential to improve patient care by streamlining PSA testing. However, a Clinical Laboratory Improvement Amendments waiver is needed before this test can be fully integrated into clinical care.
CITATION STYLE
Meyer, A. R., & Gorin, M. A. (2019, June 1). First point-of-care PSA test for prostate cancer detection. Nature Reviews Urology. Nature Publishing Group. https://doi.org/10.1038/s41585-019-0179-1
Mendeley helps you to discover research relevant for your work.